Sang Xian-Zheng, Chen Wen, Hou Xiao-Xiang, Wang Chun-Hui, Zhang Dan-Feng, Hou Li-Jun
Department of Neurosurgery, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Department of Neurosurgery, No. 905 Hospital of PLA Navy, Shanghai, China.
J Alzheimers Dis. 2024;101(3):847-876. doi: 10.3233/JAD-240270.
Emerging evidence suggests the potential of hydroxymethylglutaryl-coenzyme A (HMG-CoA, statins) as a therapeutic option for dementia.
The primary objective of this study is to assess the current state of research on statins use in dementia, with a focus on identifying pivotal questions within the field.
A systemic search for publications on statin use in dementia between 2007 and 2023 was conducted, utilizing the Web of Science Core Collection. The scientific output was analyzed from various perspectives through VOSviewer, CiteSpace, and the bibliometrics website (https://bibliometric.com/).
560 articles authored by 2,977 individuals and 999 institutions across 58 countries were included, which were published in 295 periodicals and cited 21,176 references from 16,424 authors. The annual publication output remained steady, while the number of citations increased consistently. The U.S. and Mayo Clinic emerged as the most significant country and institution, respectively. B. McGuinness and D.L. Sparks were the most eminent authors. Journal of Alzheimer's Disease was the most influential journal. Three sets of keywords and the top 10 references were identified, suggesting pivotal questions within the field.
While statins show promising potential as a treatment option for dementia, their use remains uncertain due to the reported short-term cognitive impairment events and questionable long-term protective effects against dementia. The pivotal question is to ascertain the association between statins and cognition. The mechanisms underlying the effects of statins on cognition are multifaceted. This study provides insights into the current status within the field of statin use in dementia.
新出现的证据表明，羟甲基戊二酰辅酶A（HMG-CoA，他汀类药物）有作为痴呆症治疗选择的潜力。
本研究的主要目的是评估他汀类药物用于痴呆症的研究现状，重点是确定该领域的关键问题。
利用科学网核心合集，对2007年至2023年期间关于他汀类药物用于痴呆症的出版物进行系统检索。通过VOSviewer、CiteSpace和文献计量学网站（https://bibliometric.com/）从多个角度分析科学产出。
纳入了来自58个国家的2977名个人和999个机构撰写的560篇文章，这些文章发表在295种期刊上，引用了来自16424位作者的21176篇参考文献。年出版物产出保持稳定，而引用次数持续增加。美国和梅奥诊所分别成为最重要的国家和机构。B. 麦吉尼斯和D.L. 斯帕克斯是最杰出的作者。《阿尔茨海默病杂志》是最具影响力的期刊。确定了三组关键词和前10篇参考文献，表明了该领域的关键问题。
虽然他汀类药物作为痴呆症的治疗选择显示出有前景的潜力，但由于报道的短期认知障碍事件以及对痴呆症的长期保护作用存在疑问，其使用仍不确定。关键问题是确定他汀类药物与认知之间的关联。他汀类药物对认知的影响机制是多方面的。本研究提供了对他汀类药物用于痴呆症领域当前状况的见解。
